| Date | Title | | | 05/09/13 | StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update| NEWARK, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2013 and provided a business update.
"In the first quarter, we reported the most recent data from our spinal cord injury trial, which showed that the multi-segmental gains in sensory function... |
|  | | 05/07/13 | StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business Update| NEWARK, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2013 after the market close on Thursday, May 9. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update ... |
| | | 04/18/13 | StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration| NEWARK, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the addition of the Byers Eye Institute at Stanford, located in Palo Alto, Calif., as a second site for the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD). AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwid... |
| | | 04/15/13 | StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York| NEWARK, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 2013 Regen Med Investor Day to be held on Wednesday, April 17, 2013, at the Harmonie Club, 4 East 60th Street, New York, NY. Mr. McGlynn is scheduled to make his presentation at 4:00 pm EDT. In addition, Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc... |
| | | 04/11/13 | StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's Disease| NEWARK, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has entered into an agreement with the California Institute for Regenerative Medicine (CIRM) under which CIRM will provide approximately $19.3 million to help fund preclinical development and IND-enabling activities of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) for Alzheimer's disease. The funding, which will be in the form of a forgivable loan, w... |
| | | 04/09/13 | StemCells, Inc. Closes $10 Million Debt Financing| NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed a $10 million debt financing from Silicon Valley Bank (SVB). The loan funds will be used for general corporate purposes, and increase the Company's December 31, 2013 pro forma cash balance to $34.4 million. This total also includes $2.0 million in net proceeds received subsequent to the end of the year from the exercise of warrants and the sale of shares of common stock.
"We are... |
| | | 04/09/13 | CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing| NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by StemCells, Inc. (Nasdaq:STEM), please note that in the first paragraph of the release, the pro forma cash balance date should be December 31, 2012, not December 31, 2013. All other data was correct.
CONTACT: Rodney Young
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Ian Stone
Russo Partners
(619) 308-6541
... |
| | | 03/20/13 | StemCells, Inc. Expands Patent Portfolio| NEWARK, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP+ Nestin+ cells, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated GFAP+ Nest... |
| | | 03/19/13 | StemCells, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Business Update| NEWARK, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2012.
"2012 was an eventful and positive year for StemCells, Inc.," said Martin McGlynn, President and CEO of StemCells, Inc. "We published a br... |
| | | 02/12/13 | StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains in Sensory Function Persist 12 Months After Stem Cell Transplant| Improvement From Complete to Incomplete Injury Observed in One Patient
NEWARK, Calif., Feb. 12, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the twelve-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observe... |
| | | 02/06/13 | StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference| NEWARK, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 15th Annual BIO CEO & Investor Conference to be held February 11-12 in New York City. Mr. McGlynn is scheduled to speak at 8:30 a.m. Eastern Time on Tuesday, February 12.
A live webcast of the presentation will be available through the Company's corporate website at http://investor.stemc... |
| | | 01/23/13 | StemCells, Inc. to Present at Phacilitate Cell & Gene Therapy Forum| NEWARK, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development, will make a presentation on the Company's clinical development programs at the Phacilitate Cell & Gene Therapy Forum to be held January 28-30, in Washington, DC. Dr. Tsukamoto is scheduled to speak at 12:25 p.m. ET on Wednesday, January 30, as part of the session on "Clinical development updates from leading cell and ge... |
| |
|
